IDE-034

N/A

Report date: 2026/04/03 20:03:44
First In Class

Base Information

Drug NameIDE-034
Drug Alias NameBCG034IDE034IDE-034
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-CD276Anti-PTK7DNA topoisomerase I inhibitors
TargetsCD276 antigenProtein-tyrosine kinase 7DNA topoisomerase I
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantEndometrial Neoplasms +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesBiocytogen Pharmaceuticals (Beijing) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIdeaya Biosciences IncBiocytogen Pharmaceuticals (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantEndometrial Neoplasms +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A